Figure 7. AP20187 treatment did not alter the degree of the inflammatory response in the CNS of PLP/Fv2E-PERK mice undergoing EAE. A, B, E, CD3 immunostaining showed that AP20187 treatment did not affect T-cell infiltration into the white matter of the lumbar spinal cord in PLP/Fv2E-PERK mice at PID12; 20 sections per mouse, N = 4 animals. C–E, CD11b immunostaining showed that AP20187 treatment did not change the number of microglia/macrophages present in the white matter of the lumbar spinal cord in PLP/Fv2E-PERK mice at PID12; 20 sections per mouse, N = 4 animals. F, Real-time PCR analysis showed that AP20187 treatment did not significantly alter the levels of the mRNAs encoding iNOS, TNF-α, IFN-γ, IL-4, IL-5, IL-12, IL-17, and IL-23 in the spinal cord of PLP/Fv2E-PERK mice at PID12; N = 4 animals. G, H, K, CD3 and MBP double immunostaining showed that AP20187 treatment did not change the number of T cells present in the white matter of the lumbar spinal cord in PLP/Fv2E-PERK mice at PID19; 20 sections per mouse, N = 4 animals. I–K, CD11b and MBP double immunostaining showed that AP20187 treatment did not change the number of microglia/macrophages present in the white matter of the lumbar spinal cord in PLP/Fv2E-PERK mice at PID19; 20 sections per mouse, N = 4 animals. L, Real-time PCR analysis showed that AP20187 treatment did not significantly alter the levels of the mRNAs encoding iNOS, TNF-α, IFN-γ, IL-4, IL-5, IL-12, IL-17, and IL-23 in the spinal cord of PLP/Fv2E-PERK mice at PID19; N = 4 animals. Error bars indicate SD. Scale bar: A, B, 20 μm; C, D, 60 μm; G, H, 25 μm; I, J, 25 μm.